Clinical Trial: NCT03677154
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2025-08-21 |
Study Overview
Brief Summary
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit participants with previously untreated DLBCL.
Official Title
Conditions
Intervention / Treatment
- Drug: Mosunetuzumab Intravenous (IV)
- Drug: Mosunetuzumab Subcutaneous (SC)
- Drug: Polatuzumab Vedotin
- Drug: Tocilizumab
Other Study ID Numbers
- GO40554
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2025-08-21 |
Study Overview
Brief Summary
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit participants with previously untreated DLBCL.
Official Title
Conditions
Intervention / Treatment
- Drug: Mosunetuzumab Intravenous (IV)
- Drug: Mosunetuzumab Subcutaneous (SC)
- Drug: Polatuzumab Vedotin
- Drug: Tocilizumab
Other Study ID Numbers
- GO40554